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Abstract: Cluster of Differentiation 20 (CD20) is a B-cell membrane protein that is targeted by 20 
monoclonal antibodies for the treatment of malignancies and auto-immune disorders, but 
whose structure and function are unknown. Rituximab (RTX) has been in clinical use for two 
decades, but how it activates complement to kill B cells remains poorly understood. We 
obtained a structure of CD20 in complex with RTX, revealing CD20 as a compact double-barrel 
dimer bound by two RTX antigen-binding fragments (Fabs), each of which engages a composite 25 
epitope and an extensive homotypic Fab:Fab interface. Our data suggest that RTX crosslinks 
CD20 into circular assemblies and lead to a structural model for complement recruitment. Our 
results further highlight the potential relevance of homotypic Fab:Fab interactions in targeting 
oligomeric cell-surface markers. 
 30 
 
One Sentence Summary: CryoEM structure of CD20 in complex with rituximab reveals 
membrane protein fold and explains mode of recognition of therapeutic antibody  
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Main text: The integral membrane protein Cluster of Differentiation 20 (CD20) is a B-cell-
specific marker and a clinically-validated therapeutic target for B-cell malignancies and auto-
immune conditions (1). It is ubiquitously expressed on circulating B cells (2) and is predicted to 
have four transmembrane (TM) helices with two extracellular loops, ECL1 and ECL2, the second 
of which is much longer and contains a disulfide bond (Figure S1A). These topological features 5 
are conserved among a group of membrane proteins called MS4A (membrane-spanning 4-
domain family, subfamily A), which includes 18 proteins identified through similarities between 
their amino acid sequences but whose biological functions are mostly unknown (3). Aside from 
structures of short ECL2 peptide segments from CD20 (4, 5), there exists no high-resolution 
structural data on any MS4A family member beyond predictions of secondary structure and 10 
membrane topology. While CD20 is the best-studied member of the family, even its oligomeric 
state is poorly understood: available evidence suggests it associates into homo-oligomers and 
complexes with other proteins (6–8). In addition, the function of CD20 remains an area of active 
debate. Early work suggested that CD20 functions as an ion channel because overexpression 
and knockout of CD20 can increase or decrease Ca2+ conductance in B cells, respectively (6, 9). 15 
However, more recent work showed that CD20+ B cells lacking the B-cell receptor (BCR) are 
unable to initiate calcium signaling, suggesting that CD20 indirectly regulates calcium release 
downstream from the BCR (10).  
 
 20 
CD20-targeted therapies revolutionized the treatment of B-cell malignancies and auto-immune 
disorders, starting with the monoclonal antibody (mAb) rituximab (RTX; Rituxan®), which was 
the first approved therapeutic mAb for cancer and continues to be the benchmark for second- 
and third-generation mAbs (1, 11). Another anti-CD20 mAb, ocrelizumab (OCR; Ocrevus®), is 
now used in the treatment of multiple sclerosis (12). While all anti-CD20 mAbs act by depleting 25 
B cells, they employ at least four distinct mechanisms (13): direct cell death, FcR effector 
functions through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), 
and complement-dependent cytotoxicity (CDC). Each therapeutic antibody varies in its ability to 
trigger each pathway and there is no molecular-level understanding of why this is the case, but 
these distinct functional effects have been useful in categorizing anti-CD20 mAbs into either 30 
type I or type II (1, 13). Rituximab is the prototypical type I mAb, characterized by high CDC 
activity and the ability to cluster CD20 into lipid rafts (11, 14). Other type I mAbs include OCR 
and ofatumumab (OFA; 15).  Type II mAbs such as obinutuzumab (OBZ; Gazyva®) and 
tositumomab (B1; Bexxar®) exhibit low CDC activity, lack the ability to localize CD20 into lipid 
rafts, but induce higher levels of direct cell death (16).  35 
 
 
These broad categorizations do not explain how CD20:mAb binding and mAb features lead to 
different modes of action. One hint at a possible molecular underpinning for these differences 
is that twice as many type I mAbs bind the surfaces of CD20+ cells as type II mAbs (17), 40 
suggesting that CD20:mAb binding stoichiometry plays a role, though it is not clear how such 
strict stoichiometry might arise. Adding to this mystery, some type II and type I mAbs (e.g. OBZ 
and RTX) have overlapping epitopes centered around the 170ANPSE174 motif of ECL2, while at 
least one type I mAb (OFA) has a completely separate, non-overlapping epitope involving ECL1 
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and another part of ECL2 (13). Thus, the location of the epitope on CD20 cannot be the sole 
determinant of mAb stoichiometry or of therapeutic mode of action. How do antibodies with 
virtually identical epitope sequences centered on 170ANPSE174 bind with different 
stoichiometries and trigger remarkably different responses? One hint comes from epitope fine-
mapping studies showing that residue Asn176 of ECL2 is involved in OBZ binding, but not RTX 5 
binding, and that OBZ binds to ECL2 peptides (but not CD20+ cells) with higher affinity than RTX 
(5); another hint comes from X-ray crystallographic structures of peptide-bound antigen-
binding fragments (Fabs) of RTX, OCR and OBZ, in which RTX and OCR approach the ECL2 
epitope at a similar angle, tilted approximately 70o away from the angle at which OBZ 
approaches the same peptide (4, 5, 18, 19). However, in the absence of a structure of full-10 
length CD20 or of a MS4A homologue, it is difficult to speculate how such differences in binding 
geometry might impact overall binding stoichiometry and dictate therapeutic mode of action.   
Confidential. Manuscript submitted for publication. 
 4 
Results 
CD20 forms dimers bound by two RTX Fabs 
To facilitate biophysical and structural analyses, we produced human CD20 recombinantly in 
insect cells and optimized the construct for increased expression (Figure S1A).  Following 
solubilization and purification in the mild detergent glyco-diosgenin (GDN), CD20 was found to 5 
be further stabilized by cholesterol hemisuccinate (CHS; Figure S2).  Analyzed in GDN-CHS 
buffer, size exclusion chromatography with multi-angle light scattering (SEC-MALS) indicated 
that purified CD20 forms stable complexes in 2:2 stoichiometry with RTX Fabs, and 2:1 
stoichiometry with OBZ Fabs (Figure S1C-E; Table S1).  Fab binding to purified CD20 was 
subsequently evaluated using biolayer interferometry (BLI; Figure 1A) and surface plasmon 10 
resonance (SPR; Table S2) revealing sensorgrams consistent with a 2-state 2:2 binding of RTX 
(KD = 21.4 nM, SPR), and with 2:1 binding of OBZ Fab (KD = 58.8 nM, SPR).  Imaging the resulting 
CD20:Fab complexes by negative-stain electron microscopy (nsEM) showed that each CD20 
particle is bound by either two RTX Fabs or a single OBZ Fab (Figure 1B).  Cryogenic electron 
microscopy (cryoEM) imaging of the RTX:CD20 complex allowed us to determine its structure to 15 
a resolution of 3.3 Å (Figure S3), resulting in a near-complete atomic model of the complex 
(Figure 1C). 
 
The CD20 fold 
The RTX:CD20 complex is Y-shaped, with the two RTX Fabs poised on the extracellular face of 20 
CD20. CD20 conforms to the predicted 4-transmembrane helix (TM) arrangement, with its 4 
TMs arranged anti-parallel and clockwise when viewed from the extracellular side (Figure 2, top 
view). The core of each CD20 monomer presents a compacted rectangular-fold measuring ∼25 × 
∼20 × ∼50 Å (Figure 2).  Despite low overall sequence identity across the MS4A family (∼30 %), 
the structure of CD20 reveals that key structural elements are likely shared by all members 25 
(Figure S4A). Most notable is a constellation of highly-conserved, small residues that allow for 
the close inter-helical packing observed in CD20 and are found along TM1 (Gly53, Gly60, Gly67), 
TM2 (Gly90, Ser97, Gly98), and TM3 (Ser123, Gly130) (Figure S4A).  A set of larger residues 
contributed by TM2 (Tyr86, Tyr94) and TM4 (Leu194, Met197, Ala201, Gln204) forms the bulk 
of the tightly-packed TM-helical core (Figure 2B) and are conserved as similarly-bulky residues 30 
in the MS4A family (Figure S4A). Notwithstanding some conformational heterogeneity observed 
at the intracellular end of TM1, the close interdigitation of highly-conserved residues over ∼30 
Å creates a tightly sealed 4-TM bundle within the CD20 monomer that is inconsistent with the 
formation of a transmembrane permeation pathway. 
 35 
In contrast to the conserved transmembrane core, the extracellular loops (ECLs) of the MS4A 
family are extremely diverse in sequence (Figure S4A). In CD20, the first extracellular loop 
(ECL1) is short and largely shielded by ECL2, leaving only Ile76 and Tyr77 exposed (Figure 2A). 
The first half of the approximately 35-residue-long ECL2 is an amphipathic sequence that may 
partially partition into the membrane region and surrounds the perimeter of the 4-helix bundle 40 
until it kinks into a single-turn α-helix (Asn153-Arg156), which marks the start of ECL2’s 
extracellular segment (Figure 2A). Following the α-helix, residues His158 to Ile164 form a 
circumflex-shaped cap above ECL1, and Ile164 and Tyr165 appear to plug a cavity at the center 
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of the square CD20 fold. The remaining part of ECL2 is stapled by the landmark disulfide bond 
between Cys167 and Cys183, which is located on an N-terminal extension of helix TM4 (Figure 
2, side view). This region of ECL2, akin to a turret, is by far the most solvent-accessible region of 
CD20 and contains the known peptide epitope (170ANPSE174) for most anti-CD20 antibodies (13). 
 5 
A search of the protein databank for structures similar to CD20 identified Claudin-3 and CD81 as 
the nearest matches (20, 21). Although both present similar topologies, structural superposition 
with CD20 demonstrates poor overall correspondence (Figure S4B). For example, the 
transmembrane cavity and cholesterol-coordinating acidic residue present in CD81 (20) are 
absent in CD20, and while claudins appear to share a similar core 4-TM packing with CD20, they 10 
display a different topology and distinct oligomeric assembly interfaces. We conclude that the 
three-dimensional structure of CD20 represents a distinct membrane protein fold. 
 
 
CD20 is a dimer 15 
Previous studies have suggested that CD20 exists as a dimer or a tetramer (6–8).  Viewed from 
the extracellular side, CD20 forms a dimeric double-barrel assembly of approximate dimensions 
20 × 50 Å (Figure 2, top view).  Two square CD20 subunits abut each other to form a four-helix 
anti-parallel transmembrane coiled-coil involving the upper halves of TM1 (Leu61, Phe62, 
Ala65, Leu69) and TM4 (Leu189, Ile193, Val196, Phe200) from each protomer (Figure 2D). The 20 
residues at this inter-subunit interface are involved in hydrophobic and van der Waals 
interactions. In the intracellular half of the transmembrane domain, dimerization is mediated 
by homotypic contacts between symmetry-related TM1 residues (Thr51, Ala54, Val55, Met58). 
The close, complementary packing and extensive hydrophobic surface contact at the CD20 
dimer interface does not support the existence of an inter-protomer transmembrane 25 
conduction pathway. Additionally, structure-based sequence alignment suggests that a CD20-
like dimer interface may be shared across the MS4A family (Figure S4A). 
 
The dimeric assembly of CD20 is reinforced by extensive contacts between the extracellular ⍺-
helical extension of TM4 and the solvent-exposed region of ECL2. Here, numerous hydrophobic 30 
interactions and some polar contacts (Ser179 to Ser179’; Gln181 to backbone amide of Tyr161’) 
contribute to the interface (Figure 2C).  In total, the CD20 dimer buries 1,656 Å2 of surface area 
and has a shape complementarity score of 0.53, comparable to many established dimeric 
integral membrane proteins (e.g. 22, 23).  We further examined Tyr182, located near the 
symmetry axis in CD20, and found that mutation to cysteine (Tyr182Cys) resulted in purification 35 
of a covalent dimeric species in the absence of RTX (Figure S1F), consistent with the dimeric 
assembly observed in our structure. Overall, we conclude that CD20 forms a tight dimeric 
assembly that places ECL2 loops in close proximity to each other and presents its main epitope 
(170ANPSE174) in closely associated pairs, less than 20 Å apart.  
 40 
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ECL2 of CD20 is simultaneously recognized by two RTX Fabs  
Previous studies have established that the principal epitope of RTX is centered on the ECL2 
sequence 170ANPSE174 (13). In our structure, this core epitope is simultaneously bound by two 
Fabs, which we denote RTX and RTX’ (Figure 3). The RTX Fab sits atop the CD20 protomer, 
engaging ECL2 at a shallow angle (∼	22°)  relative to the membrane plane (Figure 3, side view) , 5 
likely precluding engagement of CD20 by a single IgG. RTX engulfs the core epitope through 
numerous van der Waals packing contacts, as well as multiple polar interactions including the 
hydrogen bond pairs HC.Ser58 – Pro169 (backbone), HC.His35 – Asn171, and HC.Asn33 – 
Ser173 (backbone and side-chain). The second (RTX’) Fab extends its heavy chain variable loop 
3 (H3) across the dimer interface to present HC.Tyr97’, which interacts with Glu174 of CD20 10 
(Figure 3A). At the apex of ECL2, Ser173 organizes an extended network of hydrogen bonds 
spanning from HC.Asn33, through Glu174, to HC.Tyr97’ (Figure 3B). This key interaction 
network is clamped by both Fabs: Ser173 is stabilized by HC.Tyr52, Glu174 is sandwiched by 
HC.Trp100b and HC.Gly100’, and HC.Tyr97 is stabilized by HC.Trp100b.  
 15 
The CD20:RTX complex reveals a distinct secondary epitope 
Our structure reveals a second CD20 epitope formed by ECL1 and ECL2 and contacted by 
complementarity-determining region (CDR) loop L1 of RTX (Figure 3D). Completely distinct from 
the classic ECL2 turret epitope 170ANPSE174, this secondary epitope is recognized primarily by 
light chain residues LC.Ser28, LC.Ser29 and LC.Ser31. Residues LC.Ser28 and LC.Ser29 are 20 
positioned to make van der Waals contacts with Ile76 of ECL1 and Pro160 of ECL2, respectively. 
The side chain of LC.Ser31 is situated atop ECL2’s circumflex cap and interfaces with both CD20 
protomers: it stabilizes Tyr161 in a CH2-arene-CH2 sandwich also involving Pro160, while its 
hydroxyl moiety makes van der Waals contacts with Pro178’, which caps the TM4 α-helical 
extension of the CD20’ protomer. Earlier crystallographic studies of the primary ECL2 turret 25 
epitope in complex with RTX had measured a buried surface area of only 440 Å2 (4), but these 
L1 – ECL1/2 interactions increase the contact surface area by almost 50 %, to ~ 640 Å2 (Figure 




RTX Fabs are engaged in homotypic contacts 
The close proximity (∼	20 Å) of the two primary epitopes displayed by the CD20 dimer results in 
the RTX Fabs accommodating each other along a homotypic interface between their heavy 
chains (Figure 3). CDR loop 3 (H3) dominates the Fab:Fab interface, engaging with its symmetry 35 
mate (H3’), and with the H1’ and H2’ loops. Residue HC.Tyr97, which is germline-encoded via 
the D gene segment (Figure S6A), seems essential to the Fab-Fab interaction: its Cβ and Cγ 
atoms make close van der Waals contacts with their symmetry mates across the dimer axis, 
while its aromatic ring stabilizes the backbone of the H3 loop, and its hydroxyl hydrogen-bonds 
with Glu174’ of the contralateral CD20’ protomer (Figure 3A,B). Two key additional Fab:Fab 40 
interactions are mediated by HC.Ser31’, whose backbone and side chain directly engage 
HC.Gly99, while its side chain contacts LC.Tyr49 and HC.Tyr98 (Figure 3C). Overall, this Fab:Fab 
homotypic interface buries 375 Å2 of solvent-exposed area (Figure 4B). 
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Our structure has thus unveiled a composite CD20-Fab’ epitope with three components: the 
primary epitope on ECL2 (170ANPSE174), a secondary ECL1-ECL2 epitope, and a direct homotypic 
Fab:Fab interface. The total composite buried surface area of ~ 1,000 Å2 is comparable to 
traditional prototypical Fab:protein complexes (24), and our observations rationalize how RTX 5 
achieves nanomolar affinity for full-length CD20 (Table S2) and CD20+ cells (5) despite low 
affinity to the ECL2 epitope peptide (Table S3).  
 
RTX’s target recognition and CDC activity require the full composite epitope 
To ascertain the functional relevance of previously unobserved structural features of the 10 
complete CD20 epitope, we introduced targeted mutations into RTX (Figure 4C). We employed 
charge reversals and bulky side chains expected to disrupt these molecular interfaces and 
measured their effects on CDC (Figure 4E), and on IgG binding to purified CD20 (SPR; Table S2), 
ECL2 epitope peptide (SPR; Table S3), and CD20+ cells (flow cytometry; Figure 4D). For 
comparison, we included OBZ, which is known to bind cells at levels ~50% lower than RTX and 15 
whose Fab can only bind purified CD20 with 1:2 stoichiometry (Figure 1). 
 
RTX variants LC.Ser28Asp and LC.Ser31Asp were generated to probe the importance of the 
secondary epitope. Mutation LC.Ser28Asp resulted in reduced CD20 affinity (~20 fold), cellular 
binding (~ 25%), and CDC activity (IC50 > 10x higher) relative to wild-type RTX. LC.Ser31Asp had 20 
a notably stronger phenotype, which resulted in a ~100-fold reduction in Fab:CD20 binding, 
~50% reduction in IgG:cell binding, and nearly completely abolished CDC activity. These data 
substantiate the relevance of this secondary epitope in RTX function. 
 
We next evaluated the role of the germline-encoded HC.Tyr97, because it appears central to 25 
complex formation (see above; Figure 3A,B). The HC.Tyr97Ser mutation, which we predict may 
destabilize H3,  effectively abolishes target engagement and CDC activity, while mutation 
HC.Tyr97Phe, which removes only the terminal hydroxyl but maintains the aromaticity of the 
side chain, reduced affinity to CD20 (~15 fold) as well as cellular binding (~ 25%) and CDC 
activity (IC50 > 10x higher), suggesting that RTX function is enhanced by the polar interaction 30 
between HC.Tyr97 and Glu174’.  
 
To assess the importance of the homotypic Fab:Fab interface, we introduced mutations at 
HC.Ser31 and HC.Gly99, two positions that are reciprocally involved in interactions at the 
periphery of the complex. The HC.Ser31Glu mutant had reduced Fab:CD20 affinity (~100-fold), 35 
reduced IgG:cell binding and reduced CDC activity (>100-fold). The effect of HC.Gly99Lys was 
even more marked, with CDC completely abolished. Because these residues are not involved in 
any interactions with CD20, we conclude that homotypic Fab:Fab interactions potentiate target 
engagement, cell binding, and CDC activity of RTX.  
 40 
In summary, we have discovered several RTX mutants that, despite maintaining cell-binding 
activity comparable to that of OBZ, and largely unaffected binding to the primary ECL2 epitope, 
are incapable of eliciting CDC. This confirms that the secondary ECL1/2 epitope and Fab:Fab 
interface contribute to the unique binding properties and high CDC activity of RTX. 




Full-length RTX cross-links CD20 dimers into higher-order assemblies  
In the RTX Fab:CD20 complex, the distance between the C-termini of the Fab heavy chains 
(HC.Pro213) is greater than 120 Å, inconsistent with binding of both Fabs from a single IgG to a 5 
CD20 dimer (Figure 1C). This suggests two RTX antibodies engage the dimer, each contributing 
one of its Fab domains. To test this, we formed complexes in vitro between full-length IgG and 
CD20 and examined their structural arrangement. We found that these complexes are stable 
(Table S2), and nsEM showed that most CD20 particles were bound by two well-resolved Fabs 
in a similar geometry to that seen in the CD20:RTX Fab structure (Figure S7G). This establishes 10 
that 2:2 complex formation is not exclusive to Fab fragments and occurs readily in the context 
of full-length RTX.   
 
Unlike OBZ or the RTX Fab, RTX IgG cross-links CD20 into cyclical superstructures of 2-to-2 or 3-
to-3 IgGs and CD20s, with approximate diameters of 250 and 300 Å respectively (Figure 5A). 15 
These closed-ring assemblies feature CD20 dimers and Fc domains splayed outwards, linked by 
pairs of Fab arms which position the Fab-Fc hinges of RTX on a circle of approximate diameter 
100 Å (Figure 5A,B). Because of the striking similarity with our 3D structure of the CD20:RTX Fab 
complex, we were able to generate a model of these rings as present on the nsEM grids (Figure 
5B,C). To understand how these assemblies might relate to RTX function, we endeavored to 20 
build a model of an CD20:RTX IgG assembly as it might occur on a cell.  This was achieved by 
rotating each CD20:Fab complex 90 degrees, while keeping the ends of the Fab domains in 
close proximity to each other (Figure 5D, left). This modeled assembly exhibits precisely the 
dimensions that would be required for the three Fc domains to “fold in” (Figure 5D, middle) and 
potentially nucleate assembly of a six-membered Fc platform such as those observed in 25 
structures of the complement component C1 in complex with Fc (26). The resulting model of a 
CD20:RTX:C1 complex (Figure 5D, right) provides a structural hypothesis for how Fab:Fab and 
Fab:CD20 interactions may lay the molecular foundations that promote tight CD20 clustering 
and complement recruitment, the hallmarks of RTX. 
 30 
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Discussion 
CD20 is a clinically-validated target for the treatment of lymphomas and auto-immune diseases, 
but its structure and function have remained unknown.  In contrast to the prevailing view that 
CD20 is a tetramer (13), our structural studies establish CD20 as a compact dimeric double-
barrel assembly, with a protein fold that is distinct from any previously determined structure. 5 
Electrostatic surface calculations confirm that the transmembrane helices of CD20 are packed 
predominantly through hydrophobic and van der Waals complementary interactions. Previous 
reports have suggested the possibility that CD20 may form a plasma membrane ion channel, 
but our analyses reveal no plausible ion permeation pathway through the monomeric CD20 
protomer or along the dimeric packing interface.  We conclude that CD20 and other MS4A 10 
family members are unlikely to directly function as ion channels. 
 
The dimeric organization of CD20 finally provides a molecular-level explanation for the 
perplexing observation that twice as many type I as type II mAbs bind CD20+ cells (17). Our EM 
and biophysical studies using purified components establish that each CD20 dimer is bound by 15 
two type I RTX Fabs, but only one type II OBZ Fab. The two RTX Fabs are brought in close 
proximity due to CD20’s compact symmetrical dimeric arrangement, resulting in an extensive 
homotypic Fab:Fab interface, which necessitates a shallow angle of approach of the Fabs. This 
orientation avoids steric clashes between the two RTX Fabs, whereas OBZ’s steeper angle of 
approach (5) would be expected to sterically preclude another Fab from binding. 20 
  
Though it has long been known that RTX promotes CD20 clustering on the cell surface, our 
observation of circular RTX:CD20 assemblies with a diameter similar to that required for Fc 
hexamer formation (Figure 5A,B) raises the possibility that RTX-induced cell-surface CD20 
clusters may in fact be well-ordered assemblies specifically predisposed to recruit complement 25 
(as opposed to loose groupings on the cell surface). Assemblies of this kind could be particularly 
efficient at complement recruitment by virtue of their biasing of Fc domain positions and 
orientations towards the formation of the hexameric Fc platforms necessary for complement 
recruitment (26). In a simplistic model, we speculate that dimeric RTX:CD20 building blocks 
(Figure 1C) can assemble into a 3-to-3 closed-ring configuration that acts as a nucleating 30 
scaffold for IgG hexamer formation to ultimately recruit C1q (Figure 5D).  One unknown or 
caveat in this model is that it requires the recruitment of three additional RTX IgG molecules 
that are not involved in the initial 3-to-3 ring but are needed to achieve Fc 
hexamerization.  Once formed, it seems plausible that 3-to-3 ring assemblies could serve to 
potentiate Fc-Fc interactions by intermingling with various other RTX:CD20 superstructures 35 
(Figure 5A) or assembly intermediates that are likely found and enriched along the cell surface, 
ultimately leading to efficient Fc-hexamer formation and C1q engagement.  Although further 
experiments are needed to ascertain the precise dynamics and geometrical arrangements of 
RTX:CD20 complexes on the cell membrane when IgG hexamers are formed, our proposed 
model for C1q recruitment by RTX (Figure 5D) provides an initial molecular-level hypothesis for 40 
why type I mAbs elicit potent CDC.  This speculative structure-based model also suggests that 
CDC functionality may be shared more generally by antibodies which bind oligomeric cell-
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surface targets and leave at least one epitope unencumbered and available for further mAb 
binding.  
 
In the case of RTX, the simultaneous binding of both CD20 subunits is made possible by an 
intricate geometrical arrangement involving Fab:CD20 contacts at a secondary epitope and a 5 
large Fab:Fab interaction surface. We note that all of the RTX residues involved in this 
homotypic interaction are germline encoded in mice (Figure S6A).  This observation suggests 
that the homotypic Fab:Fab interaction was inherent to the progenitor RTX B cell prior to 
somatic hypermutation. These residues are also highly conserved among the RTX-like type I 
mAbs (Figure S6B), a majority of which are also mouse-derived.  Similar Fab:Fab contacts 10 
mediate crystal-packing of the isolated RTX Fab-ECL2 peptide complex (4) (Figure S5), which, 
taken together with our findings, indicates that Fab-Fab homotypic interactions are 
energetically favorable and an essential feature of the RTX-like type I mAbs. This raises the 
question of whether RTX Fabs may exist as pre-formed dimers prior to CD20 binding. We 
evaluated this possibility but found only weak Fab:Fab interactions at extremely high 15 
concentrations (>100 μM; data not shown), suggesting that the homotypic Fab:Fab interactions 
are nucleated by CD20 binding.  We are aware of two other examples of Fab:Fab homotypic 
interaction, and in each case, these interfaces are central to antibody function: neutralization of 
a malaria parasite (27, 28), and cross-linking-independent activation of TRAIL-R2 (29).  Given 
the functional relevance of homotypic Fab:Fab interfaces in these three exemplar cases, we 20 
propose that these observations can be exploited in the discovery and optimization of next-
generation therapeutic antibodies. 
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Figure legends 
Figure 1. Characterization of CD20:Fab complexes and cryoEM structure of CD20:RTX Fab. 
A. Biolayer interferometry (BLI) traces. A serial dilution of RTX (left) or OBZ (right) Fabs was 
flowed in for the first 1,500 seconds of the experiments, followed by a dissociation step. B. 
Negative-stain EM (nsEM) of expressed, solubilized and purified CD20 in complex with RTX 5 
(left) or OBZ (right) Fab. Scale bar: 50 Å. C. CryoEM reconstruction of the CD20:RTX Fab 
complex, at a resolution of 3.3 Å. Left panel: isosurface rendering, with the GDN micelle 
rendered in transparent grey, the RTX Fab heavy chain in purple and the light chain in pink. 
Right panel: two orthogonal side views (along the plane of the membrane) of a ribbon 
rendering of the structure. 10 
 
Figure 2. The CD20 dimer is a compact double square-barrel structure. Ribbon diagrams of the 
CD20 structure, with RTX omitted and one of the CD20 protomers transparent, for clarity. 
A. The short loop ECL1 (red), between TM1 and TM2, is almost entirely surrounded by the 
first half of ECL2 (green). B. The core of each protomer is marked by a number of highly-15 
conserved small (mostly glycine) residues (not shown) and a complementary set of bulkier 
residues shown here in space-filling representation. C, D. The extensive dimeric interface 
of CD20 involves the extracellular domain (C) as well as TM helices 1 and 4 (D). 
 
Figure 3.  Key molecular interactions between CD20 and RTX. Ribbon diagrams of the 20 
CD20:RTX Fab structure, with key amino acid side chains involved in CD20:RTX or RTX:RTX 
shown in stick representation. A. Top view of the center of the complex, where HC.Tyr97 
mediates Fab:Fab and Fab:CD20’ contacts. B. The canonical RTX epitope 170ANPSE174, in 
addition to being recognized by RTX’s heavy chain (left, purple), is also involved in a 
hydrogen bond network with Tyr97’ from the distal RTX Fab (right, grey). C. Additional 25 
Fab:Fab contacts between heavy chain (HC) loops H3 and H1 and light chain (LC) loop L2. 
D. A secondary epitope consisting of ECL1 and ECL2 is contacted by RTX’s LC loop 1.  
 
Figure 4. Multiple CD20:RTX and RTX:RTX interactions enable cell binding and CDC. A. Surface 
representation of the CD20:RTX Fab complex. The surfaces buried by complex formation 30 
are colored in yellow (CD20:RTX), orange (CD20’:RTX’), or red (RTX:RTX’). B. Open-book 
representation of the same surfaces, with surface area measurements for each buried 
surface indicated. Residues mutated as part of this study are labeled in the top left panel 
and are not involved in the primary paratope. The primary epitope (dashed line) only 
accounts for less than half (440 Å2 out of 1,015 Å2) of the total Fab binding area. C. Surface 35 
representation of the CDR face of RTX Fab, with the ECL2 turret epitope shown (green), as 
well as the positions of the point mutations under study. D,E. Complement-dependent 
cytotoxicity (D) and cell binding (E) of RTX mutants are plotted as a function of antibody 
concentration, and compared to wild-type RTX and OBZ.  
 40 
Figure 5. RTX cross-links CD20 into circular super-assemblies. A. Average nsEM images of CD20 
incubated with full-length RTX show cyclical higher-order structures of involving 2-to-2 
(top row; diameter of 250 Å) or 3-to-3 (bottom row; diameter of 300 Å) CD20-to-RTX 
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complexes. The RTX Fc domains appear disordered, presumably because of IgG hinge 
flexibility. B,C. Interpretation of an nsEM class average of a 3-to-3 assembly. D. Proposed 
model for CD20:RTX super-complex formation and complement recruitment. During nsEM 
experiments, the IgGs and solubilized CD20s are co-planar (C). Modeling these high-order 
assemblies as they might occur at the surface of CD20+ cells requires rotating the CD20:Fab 5 
complexes 90 degrees (D, left). Given the flexibility provided by the IgG hinges, it is then 
possible to position Fc domains (pink) in a common plane (D, middle). The addition of 
three further Fc domains possibly contributed by neighboring CD20:IgG assemblies (grey) 
would complete the Fc hexamer formation and enable recruitment of C1q (D, right). 
Dashed lines outline IgG molecules. Models used: structure from present work (RTX 10 
Fab:CD20 complex), EMDB-4232 (EM map of C1:Fc complex) and PDB 6FCZ (Fc domains 
and C1q head domains) (26).  
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Materials and Methods 
Recombinant expression of CD20 constructs 
All CD20 human constructs were synthesized (Genescript) and cloned into a modified pAcGP67A 
vector downstream of the polyhedron promoter. All mutations were performed using 
Quickchange mutagenesis kit (Qiagen). Recombinant baculovirus was generated using the 5 
Baculogold system (BD Biosciences) following standard protocols. Trichoplusia ni cells were 
infected for protein production and harvested 48 hrs post-infection.  
Sequence of the construct for structural studies is (the underlined sequence is the 6-His affinity 





Sequence of the construct for binding studies is (the underlined sequence is the Flag affinity tag 







Purification of CD20 for structural studies  
Trichoplusia ni cells expressing CD20 were resuspended in 25 mM Tris pH 7.5, 150 mM NaCl 
(Buffer A) supplemented with cOmplete EDTA-free protease-inhibitor cocktail tablets (Roche). 
Cell suspension was passed through a microfluidizer once at a pressure setting of 15,000 psi. 25 
Following cell lysis, suspension was spun down at 8,000 rpm for 20 min. Supernatant was then 
spun down 40,000 rpm at 4 °C for 1 hour. Isolated membranes were resuspended into Buffer A 
supplemented with 1% (w/v) GDN (Anatrace) and 0.2% (w/v) cholesterol hemisuccinate and 
solubilization was carried out with gentle agitation for 2 hrs at 4 °C. After ultracentrifugation at 
40,000 rpm at 4 °C for 30 min, clarified supernatant was mixed gently with Ni-NTA resin (Sigma) 30 
pre-equilibrated with Buffer B (25 mM Tris pH 7.5, 150 mM NaCl, 0.02% GDN) for 1 hour at 4 °C. 
Ni-NTA resin was collected by gravity flow and washed with 5 column volumes of Buffer B 
supplemented with 45 mM imidazole. His-tagged CD20 was eluted with Buffer C (25 mM Tris 
pH 7.5, 150 mM NaCl, 0.02% GDN and 250 mM imidazole). Eluate was passed over a Superdex 
S200 10/300 GL column (GE Healthcare) equilibrated in Buffer B and peak fractions were 35 
collected and incubated overnight with His-tag TEV protease (prepared in-house). Cleaved 
mixture was then passed over a fresh Ni-NTA column equilibrated with Buffer B and column 
was washed and eluted as described above. Flow through and wash fractions (containing 
untagged CD20) were collected, concentrated using an Amicon ULtra-15 Centrifugal Filter Units 
(100K MWCO, Millipore Sigma) and loaded onto a Superose 6 10/300 GL column (GE 40 
Healthcare) pre-equilibrated with Buffer B.  
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Purification of CD20 for binding studies  
Trichoplusia ni cells were co-infected with virus expressing full length CD20 (containing a C-
terminal Flag followed by an Avi-tag) along with a virus encoding for the protein BirA. Cells were 
resuspended in 25 mM Tris pH 7.5, 150 mM NaCl (Buffer A) supplemented with cOmplete 
EDTA-free protease-inhibitor cocktail tablets (Roche). Cell suspension was passed through a 5 
microfluidizer once at a pressure setting of 15,000 psi. Following cell lysis, suspension was spun 
down at 8,000 rpm for 20 min. Supernatant was then spun down 40,000 rpm at 4° for 1 hour. 
Isolated membranes were resuspended into Buffer A supplemented with 1% (w/v) GDN 
(Anatrace) and 0.2% (w/v) cholesterol hemisuccinate and solubilization was carried out with 
gentle agitation for 2 hrs at 4°C. After ultracentrifugation at 40,000 rpm at 4°C for 30 min, 10 
clarified supernatant was mixed gently with anti-M2 FLAG resin (Sigma) pre-equilibrated with 
Buffer B (25 mM Tris pH 7.5, 150 mM NaCl, 0.02% GDN) for 1 hr at 4°C. Flag resin was collected 
by gravity flow and washed with 5 column volumes of Buffer B. Flag-tagged CD20 was eluted 
with Buffer C (25 mM Tris pH 7.5, 150 mM NaCl, 0.02% GDN and 0.15 mg/mL Flag peptide. 
Eluate was passed over a Superose 10/300 GL column (GE Healthcare) equilibrated in Buffer B 15 
and peak fractions were collected. 
  
Expression and purification of recombinant antibodies and fragments 
Constructs suitable for periplasmic expression of Fab in Escherichia coli and containing 
sequences coding for either Fab fragments of RTX or OBZ were cloned; they were transformed 20 
into 34B8 E. coli cells and expressed at 30°C under control of the phoA promoter in CRAP 
phosphate-limiting autoinduction medium (30) supplemented with carbenicillin (50 μg/mL). 
After 24 hr, cells were harvested and resuspended in PBS supplemented with one complete 
EDTA-free Protease Inhibitor Cocktail tablet (Roche) per 50 mL of lysis buffer, lysozyme (0.1 
mg/mL), and benzonase (0.01 mg/mL). The prepared suspension was microfluidized at 15,000 25 
psi and clarified at 50,000 x g for 30 min at 4°C. The supernatant was then resolved on protein 
G Sepharose beads equilibrated with PBS, using 2 mL packed resin volume per original gram of 
cell paste. The column was washed extensively with PBS and Fabs were eluted under mildly 
acidic conditions (0.56 % glacial acetic acid pH 3.6). Eluted Fabs were immediately dialyzed 
overnight at 4°C against buffer containing 500 mM NaCl, 10% glycerol, and 100 mM Tris (pH 30 
8.0). Fabs was further resolved on an S75 16/60 gel filtration column (GE Healthcare) using PBS 
(pH 7.2) as the running buffer. 
Constructs for mammalian expression of IgGs were generated by gene synthesis. Plasmids 
encoding for the LC and HC were co-transfected into 293 cells and purified with affinity 
chromatography followed by SEC using standard methods (MabSelect SuRe; GE Healthcare, 35 
Piscataway, NJ, USA). 
 
CDC assay  
A complement dependent cytotoxicity (CDC) assay was set up to measure the degree of 
antibody dependent complement lysis of target cells. Human serum complement protein C1q, 40 
that binds to the Fc domain of an antibody bound to a target cell, was used to trigger the 
initiation of the complement cascade. This action eventually culminates in the formation of the 
complement protein membrane attack complex resulting in target cell lysis. The assay is 
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performed in a 96 microwell plate format and in duplicate/triplicate as follows. 50 μL of serially 
diluted (1:3) anti-CD20 mAbs and controls starting at 900 nM were incubated with 50 μL of B-
cell lymphoma WILS-2 (ATCC CRL-8885) cells (50,000) and with 50 μL of a 1:2 dilution of normal 
human serum complement (Quidel, Santa Clara, CA).  After a 2-hour incubation at 37°C, 15 μL 
of Alamar Blue (Biosource International, Camarillo, CA) was added and incubated for an 5 
additional 18 hours at 37 C. The plates were briefly shaken for 15 minutes and then read on a 
fluorescent plate reader (Ext. 535 nm, Emt 590 nm) to determine the relative fluorescent units 
(RFU). The RFU value observed was plotted relative to concentration of mAb in KaleidaGraph 
(Synergy Software, Reading, PA). Curves are plotted using a 4-parameter fit.  
   10 
Flow cytometry assay 
The relative degree of anti-CD20 mAbs binding to CD20 expressing B-cell lymphoma cell lines 
was measured by flow cytometry. Antibodies were serially diluted 1:2 in phosphate buffered 
saline containing 1% of heat inactivated fetal bovine serum (VWR Int. Radnor, PA). 50 μL of the 
diluted mAbs was dispensed into U-bottom 96-well plates. The concentrations ranged from 200 15 
nM  to 0.82 nM.  Next, each well received 100,000 WIL2-S (ATCC CRL-8885) B-cell lymphoma 
cells in a 50 ul volume. The plates were gently mixed and incubated on ice. Following a 1-hr 
incubation, the cells were pelleted and washed 5 times in cold PBS. 1 ug of a FITC-conjugated 
goat anti-human Fc specific F(ab’)2 (Jackson Immunoresearch, West Grove, PA) was added to 
each well. After a 30-minute incubation on ice, the cells were pelleted, washed in cold PBS 3-20 
times and then fixed in PBS containing 4% paraformaldehyde (ThermoScientific, Rockford, IL). 
Cells were analyzed using a BD Biosciences LSRFortessa (San Jose, CA) to determine the 
geometric MFI (median, fluorescence intensity) of antibody binding to cells. 
  
BLI binding studies 25 
Biotinylated CD20 was captured on streptavidin SA biosensors (FortéBio / Molecular Devices) at 
10 μg/mL for 180 seconds and washed to remove any unbound material before conducting 
measurements in Buffer B supplemented with 0.5 mg/mL BSA. The kinetic data were fit to a 
simple 1:1 binding model to determine the affinity constant (KD) using the association (Kon) and 
dissociation (Koff) rates. Binding assays were performed in triplicate and average KD values 30 
reported with SDs. Buffer containing 0.02% GDN supplemented with 0.002% CHS was used for 
all washes and dilutions. Sensorgrams were normalized to a reference well containing only 
buffer. 
 
SPR binding studies 35 
Binding studies were conducted using on a 8K Biacore instrument by immobilizing onto a 
Sensor Chip C1 (GE LifeSciences), which had been immobilized with 500-800 RU of neutravidin.  
The N-terminal avi-tagged CD20 was immobilized in the presence of 50 mM HEPES pH 7.5, 150 
mM NaCl, 0.2% GDN to a density ~40 RU. A amino-terminally biotinylated (PEGx6) linear 
peptide with the CD20 epitope (163NIYNCEPANPSEKNSPSTQYCYSIQ187), which had been 40 
synthesized using standard solid-phase Fmoc chemistry and purified with reverse phase HPLC 
(31), was immobilized under similar conditions to a density of ~15 RU.  The full length IgG and 
Fab fragments were added using single cycle kinetic methods with 100 second associations at 
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20 °C and 500 s dissociation phase at 50 µL/min depending. The data was referenced to an un-
immobilized neutravidin surface and a blank injection. Non-specific binding to the chip surface 
was subtracted from each curve. Data was analyzed using Biacore Evaluation software and 
curves were fit using 1:1 and 2-state kinetic fits. 
  5 
Complex formation  
Recombinant CD20 was incubated with a molar excess of IgG or Fab and incubated on ice for 30 
min. Reaction was passed over a Superose 6 10/300 GL column (GE Healthcare) equilibrated in 
25 mM Tris pH 7.5, 150 mM NaCl, 0.02% GDN and peak fractions were collected. 
  10 
Negative stain analysis 
Complexes were diluted to 0.01 mg/mL in buffer B and 4 µL of the solution was placed onto a 
CF2/1 300 grid from Electron Microscopy Sciences (EMS) previously cleaned using a GloQube 
glow discharge (Quorum Technologies) system. After 30 sec incubation, sample was blotted 
with Whatman paper, dipped three times into 30 µL of distilled water and stained twice into 30 15 
µL of a filtered solution of 2% uranyl acetate. Grids were imaged using a 200 KV Talos F200c 
with a CETA camera (ThermoFischer Scientific) and 2D class averages were computed using 
cisTEM (32). 
 
Differential scanning fluorimetry 20 
Melting experiments were conducted on a Prometheus NT48 (NanoTemper technologies) by 
measuring the tryptophan fluorescence 330/350 nm ratio of protein samples concentrated at 
0.3 mg/mL in a standard capillary. 
 
SEC-MALS analysis 25 
Purified proteins and complexes were run on a Waters XBridge BEH S200 A gel filtration column 
equilibrated in 25 mM Tris pH 7.5, 150 mM NaCl, 0.02% GDN in line with a Dawn HELEOS II 
(Wyatt Technologies) light scattering detector connected to a Wyatt OptiLab rEX refractive 
index detector. Wyatt Technologies software (ASTRA) was used to determine the corresponding 
peaks' molecular weight based on the refractive index. In order to determine the unbiased 30 
molecular weight of the apo CD20 protein, the protein conjugate analysis within the ASTRA 
software was performed. Because the dn/dc value for this detergent is unknown, a value of 
0.143 mL/gm was arbitrary used to calculate the molecular weight of the GDN micelle (dn/dc 
values for most detergents is usually comprised between 0.1 and 0.15 ml/gm). 
 35 
Cryo-EM sample preparation and data acquisition 
Recombinant CD20 was incubated with Rituxan Fab at 1:1.2 molar ratio and incubated on ice 
for 30 min. Mixture was injected over a Superose 6 Increase 3.2/300 column (GE Healthcare) 
equilibrated in 25 mM Tris pH 7.5, 150 mM NaCl, 0.01% GDN. 3.5 µL of the peak fraction of 
CD20/Rituxan Fab complex at a concentration of 2 mg/mL was applied to a glow-discharged C-40 
flat holey carbon grid (CF-1.2/1.3-2C, Electron Microscopy Sciences) coated with a thin layer of 
gold. Grids were blotted in Vitrobot Mark IV (ThermoFisher Scientific) using 5 s blotting time 
with 100% humidity, and then plunge-frozen in liquid ethane cooled by liquid nitrogen. A total 
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of 24,743 movie stacks were collected with SerialEM (33) on a Titan Krios (Thermo Fisher 
Scientific) operated at 300 kV and equipped with a BioQuantum energy filter operated with a 
20eV energy slit with a K2 Summit direct electron detector camera (Gatan). Images were 
recorded at a nominal magnification of 165000 x, corresponding to a pixel size of 0.849 Å per 
pixel. Each image stack contains 40 frames recorded every 0.25 s giving an accumulated dose of 5 
53 electrons/Å² and a total exposure time of 10 s. Images were recorded with a set defocus 
range of 0.5 to 1.5 µm. 
 
Structure determination 
All image processing was performed with cisTEM (32). For the 3D structure of CD20 bound by 10 
RTX Fab, the processing scheme was as depicted in Figure S3C. For atomic model building, PDB 
2OSL was used to place the ECL2 peptide epitope and an initial model of CD20 was built by 
extending this manually in Coot (34). The model for the RTX Fab was started from PDB 4KAQ. 
This complete model was then rebuilt using interactive molecular dynamics (35), and refined in 
real space (36). 15 
 
Structure analysis 
Protein-protein shape complementarity was calculated using the program SC (37). Figure 
preparation and computation of buried solvent-accessible surface area was done with 
ChimeraX (38). 3D homology structural alignments were performed using the DALI server (39) 20 
and sequence alignments was using EMBL-EBI’s Clustal Omega Multiple Sequence Alignment 
tool (40) followed by structure-guided manual curation. 
 
 
  25 
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Table S1: MALS estimates of CD20:Fab molecular weights 
 Estimated molecular weight  of complex   
(kDa) 
Relative to apo CD20  
(kDa) 
CD20 308.7 (± 3.7 %) 0.0  
CD20 + RTX Fab 386.7 (± 3.8 %) 78.0  
CD20 + OBZ Fab 348.2 (± 3.6 %) 39.5 
Estimated MW includes CD20’s detergent GDN micelle and does not correspond to the protein 
molecular weight. 
 
Table S2: Affinity of mAbs to immobilized full-length CD20 5 
mAb KD (nM) Average SE (%) Kinetics Chi2 (RU2) 
RTX 1.65 3.44 0.36 
OBZ 12.33 1.01 0.10 
RTX (Fab) 21.4 0.55 0.22 
OBZ (Fab) 58.8 0.55 0.47 
RTX HC.Y97F 24.75 3.77 1.21 
RTX HC.Y97S > 1500 N/A N/A 
RTX HC.S31E 100.35 1.82 1.01 
RTX HC.G99K 468.5 0.59 0.24 
RTX LC.S28D 37.95 2.93 1.21 
RTX LC.S31D 136 2.79 1.17 
Surface plasmon resonance measurements of mAb affinity for CD20. For each parameter, the 
average value (n=2) is shown. Data were fit using a two-state reaction model for all molecules 
tested. A 1:1 binding model did not fit well to either RTX or OBZ sensorgrams (data not shown). 
 
 10 
Table S3: Affinity of mAbs to immobilized CD20 epitope peptide 
mAb KD (μM) Average SE (%) Kinetics Chi2 (RU2) 
RTX 0.642 18 0.797 
OBZ 0.347 16 4 
RTX HC.Y97F 1.21 9.7 0.06 
RTX HC.Y97S No binding N/A N/A 
RTX LC.S28D 2.31 12.8 0.013 
RTX LC.S31D 3.75 15.9 0.0128 
Surface plasmon resonance measurements of IgG affinity for CD20 peptide were fit using a 1:1 
steady state model.  
 
 15 
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Table S4: cryoEM 
 
Data collection 
 Microscope      ThermoFisher Titan Krios 
 Acceleration voltage     300 kV 5 
 Detector      Gatan K2 
 Energy filter      Gatan BioQuantum 
 Energy filter slit width     20 eV 
 Image pixel size     0.849 Å 
 Electron exposure     48.5 e-/Å2  10 
 Number of frames     40 
 
Image processing 
 Number of micrographs    24,743 
 Number of picks (“soft disc” template)  4,114,800 15 
 Number of particles used    466,362 
 Pixel size for processing & reconstruction  1.0 Å 
 Box size      310 pixels 
 Symmetry      C2 
 Number of particles for final reconstruction  155,719 20 
 Highest resolution used in refinement  5.0 Å   
 Global resolution (FSC = 0.143)   3.3 Å 
 
Model building & refinement 
 Software used (de novo build)   coot 25 
 Software used (refinement)    ISOLDE, Phenix 
 Number of amino acid residues   1,196 
  
Model validation (Molprobity) 
 MolProbity score     1.54 30 
All-atom clashscore     4.71 
 Ramachandran plot 
favored     95.72 % 
  allowed     4.19 % 
  outliers     0.08 % 35 
 Rotamer outliers     0.49 % 
 Cβ deviations      0.72 % 
 Peptide plane 
  cis-proline     15.25 %  
  cis-general     0.00 % 40 
  twisted proline    0.00 %  
  twisted general    0.00 % 
 CaBLAM outliers     1.10 % 
Confidential. Manuscript submitted for publication. 
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Supplementary Figure legends 
Figure S1. CD20 constructs, expression, purification and characterization. A. Topological map 
of CD20 constructs used in this study. The construct used for EM studies was amino-
terminally truncated at residue Thr41, and carboxy-terminally His-tagged. The full-length 
construct was N-terminal FLAG-Avi-tagged for binding studies. B. Primary sequence of 5 
CD20, annotated with secondary-structure elements. Amino acid residues involved in 
interactions with RTX Fabs are labeled in pink (light chain) or purple (heavy chain). C. SEC-
MALS analysis of detergent-solubilized, purified CD20 reveals a protein molecular mass of 
approximately 67 kDa, consistent with a CD20 dimer. Estimated molecular weight of CD20 
embedded within a detergent micelle was determined by subtracting the estimated size of 10 
the GDN micelle using the “protein conjugate” feature of the ASTRA software (Wyatt 
Technology). An arbitrary dn/dc value of 0.143 mL/g was attributed to GDN. D. SEC elution 
profiles of CD20 alone (blue), CD20 with OBZ Fab (red), or CD20 with RTX Fab (black) show 
that RTX and OBZ Fabs form stable complexes with purified CD20, and that the CD20:RTX 
complex is of larger dimensions than the CD20:OBZ complex. E. BLI equilibrium values 15 
from Figure 1A are plotted as a function of Fab concentration, indicating that 
approximately 2 times more RTX than OBZ Fabs bind to immobilized CD20. Fitting of these 
data with a 1:1 binding model suggests apparent KD values of 49 nM for RTX and 70 nM for 
OBZ. F. SDS-PAGE analysis of recombinant wild type full length CD20 and Tyr182Cys 
mutant under non-reducing and reducing conditions (10 mM TCEP, 5 minutes). Under 20 
native conditions, Tyr182Cys mutant runs at a molecular weight consistent with a CD20 
dimer; upon addition of reducing agent, band collapses down to the equivalent of a CD20 
monomer suggesting mutant was expressed as a disulfide linked dimer. Migration of wild 
type protein is unchanged regardless of the reducing conditions. 
 25 
Figure S2. Cholesterol hemisuccinate stabilizes CD20. A. Experimental workflow of sample 
preparation. Full length CD20 was solubilized in 1% GDN in absence or presence of 0.2% 
CHS and purified over Ni-NTA column. Concentrated eluates were then diluted 100 fold 
into CHS free buffer (blue or orange traces, respectively) or into buffer supplemented with 
0.002% CHS (red and black traces). Standard error was calculated from three technical 30 
replicates. B. Differential scanning fluorimetry of CD20 purified in presence or absence of 
cholesterol measured on NanoDSF instrument. Curves are average of three replicates. For 
cryoEM studies, CHS was added at the time of solubilization. 
 
Figure S3. CryoEM structure determination of CD20:RTX Fab. A. Representative micrograph. B. 35 
Representative 2D class averages. C. Single-particle image processing workflow. D. Fourier 
Shell Correlation (FSC) between two half datasets yields a global resolution estimate of ~ 
3.3 Å. No spatial frequencies beyond 1/5 Å-1 were used at any point during refinement. E. 
Heat map representation of the distribution of assigned particle orientations shows a bias 
towards side views (near the periphery of the plot). F. Isosurface rendering of the 3D map 40 
with surface coloring according to the local resolution estimated by windowed FSCs (41). 
G. Map details showing side chains in stick representation and a mesh representation of 
Confidential. Manuscript submitted for publication. 
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the 3D Coulomb potential map, contoured at the indicated σ level (where σ is one 
standard deviation above the mean of the map values). 
 
Figure S4. The MS4A family and nearest structural homologues of CD20. A. Multi-sequence 
alignment of CD20 (MS4A1) and selected members of the MS4A family. Clustal 5 
conservation is denoted by asterisk (*; fully conserved residue), colon (:; strongly similar 
properties), period (.; weakly similar properties). B. Cartoon renderings of CD20 and the 
two closest structural homologues identified, claudin-3 and CD81. In the case of claudin-3, 
sequence or topology-based alignments do not give good structural overlap (“topological 
alignment”); a slightly better 3D alignment can be obtained by ignoring the sequence and 10 
connectivity of the TM helices (“3D TM alignment”). 
 
Figure S5. The CDR surface of RTX is also involved in mediating Fab:Fab contacts in 
crystallography experiments. A. Bottom and side views of RTX Fab in complex with CD20 
or ECL2 peptide, as visualized with cryoEM (this work) or X-ray crystallography (4) 15 
respectively. For clarity and ease of comparison, the non-ECL2-turret parts of CD20 are 
hidden from the cryoEM structure. The structures were aligned by superposing CD20 
residues 170 to 175, which constitute the core of the main RTX epitope. B. Heavy-chain 
loop 3 adopts significantly different conformations in the cryoEM and X-ray crystallography 
structures.  20 
 
 
Figure S6. Sequence analysis of RTX and other anti-CD20 antibodies. A. Sequences of RTX and 
mouse germline. B. Multi-sequence alignment of notable anti-CD20 antibodies. Type I 
antibodies with overlapping ECL2 turret epitopes are shown in black. Ofatumumab, which 25 
is also a type I antibody, but binds a composite ECL1/ECL2 epitope is shown in blue. Type II 
mAbs are shown in purple. 
 
 
Figure S7. Full-length IgG RTX and OBZ complex formation with CD20. A. Size exclusion 30 
chromatography profiles of CD20 complexed with an excess of OBZ IgG (blue trace) or RTX 
IgG (red). CD20:RTX elution profile suggests the presence of multiple distinct species 
whereas CD20:OBZ co-elution peak suggests a unique species, although slightly 
asymmetrical. B. SDS-PAGE associated to SEC profiles shown in panel A. Fractions 
underlined corresponds to co-elution fractions. C. SPR sensorgram. RTX and OBZ (red and 35 
blue respectively) were injected in increasing concentrations over surface immobilized 
CD20.  Under saturating conditions the RTX shows a 2:1 stoichiometry compared to the 
OBZ binding to CD20. Injection spikes were removed for clarity. D. Biolayer interferometry 
(BLI) traces representing binding of a dilution series of Rituxan IgG to immobilized 
biotinylated CD20. Sensograms were normalized to a reference well containing only 40 
buffer. E. Biolayer interferometry (BLI) traces representing binding of a dilution series of 
Gazyva IgG to immobilized biotinylated CD20. Sensograms were normalized to a reference 
well containing only buffer. F. BLI equilibrium values from panels D and E are plotted as a 
function of IgG concentration. Fitting of these data with a 1:1 binding model suggests 
Confidential. Manuscript submitted for publication. 
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apparent KD values of 1.7 nM for RTX (red trace) and 3.3 nM for OBZ (blue traces) 
consistent with SPR measurements of the same (Table S2). G. Representative micrograph 
of negative-stain EM analysis of purified CD20 in complex with RTX (left) or OBZ (right) IgG 
(see Figure S1, panel A and B). A representative cyclical superstructure is highlighted by a 
white box. 5 
Figure 1
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SDS-PAGE: dimer mutant cross-linking
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Light chain variable region
Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
Rituxan Q I V L S Q S P A I L S A S P G E K V T M T C R A S S S V S Y I H W F Q Q K P G S S P K P W I Y A T S N L A S G
Germline Q I V L S Q S P A I L S A S P G E K V T M T C R A S S S V S Y M H W Y Q Q K P G S S P K P W I Y A T S N L A S GC C C C C C C C C C
Kabat number 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95
a
















Rituxan V P V R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W T S N P . P T F G G G T K L E I K
Germline V P A R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W S S N P P W T F G G G T K L E I KC C C C C C C
Heavy chain variable region
Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52
a
53 54 55 56 57 58 59 60 61 62 63 64 65
Rituxan Q V Q L Q Q P G A E L V K P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P G R G L E W I G A I Y P G N G D T S Y N Q K F K G
Germline Q A Y L Q Q S G A E L V R P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P R Q G L E W I G A I Y P G N G D T S Y N Q K F K GC C C C C










































Rituxan K A T L T A D K S S S T A Y M Q L S S L T S E D S A V Y Y C A R S T Y Y G G D W Y F N V W G A G T T V T V S A
Germline K A T L T V D K S S S T A Y M Q L S S L T S E D S A V Y F C A R - - Y Y G Y D W Y F D V W G A G T T V T V S SC C C C C C C C C C C C C C C C C
CDR H1 - Chothia
CDR H1 - Kabat
CDR H3 - Kabat
CDR L2 - Contact
CDR L2 - Chothia
CDR L2 - Kabat
CDR L3 - Contact
CDR L3 - Chothia
CDR L3 - Kabat
CDR H1 - Contact
CDR L1 - Contact
CDR L1 - Chothia
CDR L1 - Kabat
CDR H2 - Contact
CDR H2 - Chothia
CDR H2 - Kabat
CDR H3 - Contact
CDR H3 - Chothia
Light chain variable region










28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
Rituxan Q I V L S Q S P A I L S A S P G E K V T M T C R A S . . . . . . S S V S Y I H W F Q Q K P G S S P K P W I Y A T S N L A S G
1F5 Q I V L S Q S P A I L S A S P G E K V T M T C R A S . . . . . . S S L S F M H W Y Q Q K P G S S P K P W I Y A T S N L A S G
2H7 Q I V L S Q S P A I L S A S P G E K V T M T C R A S . . . . . . S S V S Y M H W Y Q Q K P G S S P K P W I Y A P S N L A S G
Ocaratuzumab E I V L T Q S P G T L S L S P G E R A T L S C R A S . . . . . . S S V P Y I H W Y Q Q K P G Q A P R L L I Y A T S A L A S G
Ublituximab Q I V L S Q S P A I L S A S P G E K V T M T C R A S . . . . . . S S V S Y M H W Y Q Q K P G S S P K P W I Y A T S N L A S G
Ofatumumab E I V L T Q S P A T L S L S P G E R A T L S C R A S Q . . . . . S V S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G
11B8 E I V L T Q S P A T L S L S P G E R A T L S C R A S Q . . . . . S V S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G
B1 Q I V L S Q S P A I L S A S P G E K V T M T C R A S . . . . . . S S V S Y I H W F Q Q K P G S S P K P W I Y A T S N L A S G
Obinutuzumab/Gazyva D I V M T Q T P L S L P V T P G E P A S I S C R S S K S L L H S N G I T Y L Y W Y L Q K P G Q S P Q L L I Y Q M S N L V S GC C C C C C C C C C C C C C C C
















Rituxan V P V R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W T S N P P T F G G G T K L E I K
1F5 V P A R F S G S G S G T S Y S L T I S R V E A E D A A T Y F C H Q W S S N P L T F G A G T K L E L K
2H7 V P A R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W S F N P P T F G A G T K L E L K
Ocaratuzumab I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q W L S N P P T F G Q G T K L E I K
Ublituximab V P A R F S G S G S G T S Y S F T I S R V E A E D A A T Y Y C Q Q W T F N P P T F G G G T R L E I K
Ofatumumab I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S N W P I T F G Q G T R L E I K
11B8 I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S D W P L T F G G G T K V E I K
B1 V P V R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W T S N P P T F G G G T K L E L K
Obinutuzumab/Gazyva V P D R F S G S G S G T D F T L K I S R V E A E D V G V Y Y C A Q N L E L P Y T F G G G T K V E I KC C C C C C C
CDR L2 - Contact
CDR L2 - Chothia
CDR L2 - Kabat
CDR L3 - Contact
CDR L3 - Chothia
CDR L3 - Kabat
CDR L1 - Contact
CDR L1 - Chothia
CDR L1 - Kabat
Heavy chain variable region
Kabat number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52
a
53 54 55 56 57 58 59 60 61 62 63 64 65
Rituxan Q V Q L Q Q P G A E L V K P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P G R G L E W I G A I Y P G N G D T S Y N Q K F K G
1F5 Q V Q L R Q P G A E L V K P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P G Q G L E W I G A I Y P G N G D T S Y N Q K F K G
2H7 Q A Y L Q Q S G A E L V R P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P R Q G L E W I G A I Y P G N G D T S Y N Q K F K G
Ocaratuzumab E V Q L V Q S G A E V K K P G E S L K I S C K G S G R T F T S Y N M H W V R Q M P G K G L E W M G A I Y P L T G D T S Y N Q K S K L
Ublituximab Q A Y L Q Q S G A E L V R P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P R Q G L E W I G G I Y P G N G D T S Y N Q K F K G
Ofatumumab E V Q L V E S G G G L V Q P G R S L R L S C A A S G F T F N D Y A M H W V R Q A P G K G L E W V S T I S W N S G S I G Y A D S V K G
11B8 E V Q L V Q S G G G L V H P G G S L R L S C T G S G F T F S Y H A M H W V R Q A P G K G L E W V S I I G . T G G V T Y Y A D S V K G
B1 Q A Y L Q Q S G A E L V R P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P G R G L E W I G A I Y P G N G D T S Y N Q K F K G
Obinutuzumab/Gazyva Q V Q L V Q S G A E V K K P G S S V K V S C K A S G Y A F S Y S W I N W V R Q A P G Q G L E W M G R I F P G D G D T D Y N G K F K GC C C C C




















































Rituxan K A T L T A D K S S S T A Y M Q L S S L T S E D S A V Y Y C A R S T Y Y G G D W Y F . . . . . N V W G A G T T V T V S A
1F5 K A T L T A D K S S S T A Y M Q L S S L T S E D S A V Y Y C A R S H Y G S N Y V D Y F . . . . D Y W G Q G T T L T V S S
2H7 K A T L T V D K S S S T A Y M Q L S S L T S E D S A V Y F C A R V V Y Y S N S Y W Y F . . . . D V W G T G T T V T V S A
Ocaratuzumab Q V T I S A D K S I S T A Y L Q W S S L K A S D T A M Y Y C A R S T Y V G G D W Q F . . . . . D V W G K G T T V T V S S
Ublituximab K A T L T V G K S S S T A Y M Q L S S L T S E D S A V Y F C A R Y D Y N Y A M . . . . . . . . D Y W G Q G T S V T V S S
Ofatumumab R F T I S R D N A K K S L Y L Q M N S L R A E D T A L Y Y C A K D I Q Y G N Y Y Y G M . . . . D V W G Q G T T V T V S S
11B8 R F T I S R D N V K N S L Y L Q M N S L R A E D M A V Y Y C A R D Y Y G A G S F Y D G L Y G M D V W G Q G T T V T V S S
B1 K A T L T V D K S S S T A Y M Q L S S L T S E D S A V Y F C A R V V Y Y S N S Y W Y F . . . . D V W G T G T T V T V S A
Obinutuzumab/Gazyva R V T I T A D K S T S T A Y M E L S S L R S E D T A V Y Y C A R N V F D G Y W L . . . . . . . V Y W G Q G T L V T V S SC C C C C C C C C C C C C C C C C
CDR H1 - Contact
CDR H1 - Chothia
CDR H1 - Kabat
CDR H3 - Kabat
CDR H2 - Contact
CDR H2 - Chothia
CDR H2 - Kabat
CDR H3 - Contact
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